{
    "symbol": "NRXP",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-16 11:05:03",
    "content": " Based on the FDA's input, we performed a post hoc analysis of our completed Phase 2b/3 study focused on the approximately 70% of patients that continue to progress the COVID-19 respiratory failure that also received treatment Remdesivir. Research and development expenses for the three months ended March 31st, 2022 totaled $5.5 million, compared to $2.9 million for the quarter ended March 31st, 2021. General and administrative expenses for the three months ended March 31st, 2022 totaled $10.2 million compared to $2.1 million for the three months ended March 31st, 2021. The $10.2 million and $2.1 million of general and administrative expenses for the three months ended March 31st, 2022 and 2021 included $1.1 million and $0.3 million, respectively, of non-cash stock-based compensation. For the three months ended March 31st, 2022, NRX Pharmaceuticals recorded gains of $2.1 million and $0.2 million for the change in fair value of earn-out cash liability, and warrant liability, respectively. For the three months ended March 31st, 2021, NRX Pharmaceuticals recorded reimbursement expenses from Relief Therapeutics of $0.8 million, a $0.1 million gain on extinguishment of debt and a non-cash settlement expense of $21.4 million related to the gym warrant. Net loss for the three months ended March 31, 2022 was $13.4 million or $0.21 per share compared with a net loss of $25.5 million or $0.71 per share for the three months ended March 31, 2021. For the three months ended March 31st, 2022, NRX Pharmaceuticals used $10.4 million of cash in operating activities, compared to $3.0 million during the three months ended March 31st, 2021."
}